9,11-Epoxy-9-homo-14-oxaprosta-5-enoic acid derivatives. Novel inhibitors of fatty acid cyclooxygenase

Citations Over Time

Abstract

A novel bicyclic prostaglandin analogue, [1R-[l alpha,2 beta (5Z),3 beta,4 alpha]]-7-[3-[(hexyloxy)methyl]- 7-oxabicyclo[2.2.1]hept-2-yl]-5-heptenoic acid (1), and cogeners were found to be potent inhibitors of fatty acid cyclooxygenase. Compound 1 was the only stereoisomer out of eight possible structures that was active. Ether 1 was 20 times more potent than indomethacin (IND) in inhibiting arachidonic acid (AA) induced aggregation of human platelet-rich plasma. Compound 1 was also more potent than IND in several in vivo assays, AA-induced sudden death in the conscious mouse (2 times) and AA-induced bronchoconstriction in the anesthetized guinea pig (16-45 times).

Related Papers

• → Convergent Oxygenation of Arachidonic Acid by 5-Lipoxygenase and Cyclooxygenase-2(2005)36 cited
• → Role of COX-2 in the Enhanced Vasoconstrictor Effect of Arachidonic Acid in the Diabetic Rat Kidney(2003)53 cited
• → Inhibition of COX activity by NSAIDs or ascorbate increases cAMP levels and enhances differentiation in 1α,25-dihydroxyvitamin D3-induced HL-60 cells(2005)17 cited
• → Unraveling how the Gly526Ser mutation arrests prostaglandin formation from arachidonic acid catalyzed by cyclooxygenase-2: a combined molecular dynamics and QM/MM study(2020)4 cited
• → Action of bradykinin at the cyclooxygenase step in prostanoid synthesis through the arachidonic acid cascade(1991)12 cited